局限期前列腺癌大分割放疗与中度大分割方案的疗效比较
中位随访10.3年,45 Gy/9次组10年PFS、bRFS、OS分别为78.1%、93.3%、84.3%,无前列腺癌相关死亡。匹配分析显示两组10年OS、PFS、无失败生存无显著差异,45 Gy/9次组胃肠道毒性显著更低(P=0.018),泌尿生殖毒性无显著差异(P=0.757)。
要点
- 45 Gy/9次大分割放疗在局限期前列腺癌中显示良好长期生存,10年PFS 78.1%、OS 84.3%。
- 匹配分析中45 Gy/9次与67.5 Gy/25次方案肿瘤学结局无显著差异。
- 45 Gy/9次组胃肠道毒性显著低于中度大分割组(P=0.018),泌尿生殖毒性无差异。
核心结论
- 45 Gy/9次大分割放疗在局限期前列腺癌中显示令人鼓舞的生存结局和可接受的毒性。
- 倾向评分匹配分析中,45 Gy/9次与67.5 Gy/25次方案肿瘤学结局无统计学显著差异,且45 Gy/9次组胃肠道毒性更低。
研究设计与样本
- 另选取同中心2009年2月至2019年10月95例接受中度大分割方案治疗的患者,采用倾向评分匹配平衡混杂偏倚。
- 主要终点为无进展生存(PFS),次要终点包括总生存(OS)、生化复发无生存(bRFS)、前列腺癌特异生存(PCSS)及泌尿生殖(GU)和胃肠道(GI)毒性。
主要发现
- 中位随访10.3年,45 Gy/9次组10年PFS、bRFS、OS分别为78.1%、93.3%、84.3%,无前列腺癌相关死亡。
- 倾向评分匹配后纳入60例可比较患者:67.5 Gy/25次组36例,45 Gy/9次组24例。
- 两组10年OS(72.1% vs. 73.5%,P=0.583)、PFS(68.8% vs. 75%,P=0.205)、无失败生存(95.8% vs. 94.0%,P=0.757)均无显著差异。
- 45 Gy/9次组胃肠道毒性显著低于中度大分割组(P=0.018),泌尿生殖毒性两组无显著差异(P=0.757)。
关键数值与推荐
- 大分割方案为45 Gy分9次;中度大分割方案为67.5 Gy分25次。
- 毒性评估采用美国国家癌症研究所常见不良事件评价标准(CTCAE)3.0版和放射治疗肿瘤学组(RTOG)晚期并发症标准,评估≥2级GU和GI毒性。
- 倾向评分匹配分析中胃肠道毒性比较P=0.018,泌尿生殖毒性比较P=0.757。
临床怎么用
- 45 Gy/9次大分割放疗可作为局限期前列腺癌的一种治疗选择,具有时间效率优势。
- 该方案与中度大分割方案肿瘤学结局相当,且可能降低胃肠道毒性,但需结合样本量有限和非随机设计谨慎解读。
局限性
- 样本量有限,匹配后仅60例可比较患者。
- 非随机设计,尽管采用倾向评分匹配,仍可能存在残余混杂。
- 两个队列之间存在技术差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of Prostate cancer (PC) has risen steadily in China, and hypofractionated radiotherapy offers a biologically advantageous and time-efficient treatment strategy. However, long-term data in Chinese populations are limited. This study evaluated the 10-year outcomes of hypofractionated radiotherapy regimen (45 Gy in 9 fractions) for localized PC. A propensity score-matched comparison was conducted to contextualize its effectiveness and toxicity relative to a moderately hypofractionated regimen. METHODS: From October 2011 to April 2017, thirty patients with localized PC who received hypofractionated radiotherapy (45 Gy in 9 fractions) were enrolled in this prospective trial. Ninety-five patients treated with a moderately hypofractionated regimen at the same center between February 2009 and October 2019 were selected. The propensity score matching (PSM) was applied to balance the potential confounding bias. Survival outcomes were analyzed using the Kaplan-Meier method. Genitourinary (GU) and gastrointestinal (GI) toxicities (grade ≥ 2) were assessed using the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 3.0) and Radiation Therapy Oncology Group late morbidity criteria. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), biochemical recurrence-free survival (bRFS), PC-specific survival (PCSS), and GU and GI toxicities. RESULTS: After a median follow-up of 10.3 years, patients treated with the 45 Gy in 9 fractions regimen achieved favorable long-term outcomes, with the 10-year PFS, bRFS, and OS rates of 78.1%, 93.3%, and 84.3%, respectively, with no prostate cancer-related deaths. PSM analysis yielded 60 comparable patients: (36 in the 67.5 Gy/25 fractions group and 24 in the 45 Gy//9 fractions group). No significant differences were observed between the 45 Gy/9 fractions and 67.5 Gy/25 fractions groups in 10-year OS (72.1% vs. 73.5%, P = 0.583), PFS (68.8% vs. 75%,P = 0.205), or freedom from failure(95.8% vs.94.0%, P = 0.757) Regarding toxicity, the 45 Gy /9 fractions was associated with significantly lower GI toxicity compared with the moderately hypofractionated regimen (P = 0.018), whereas GU toxicity did not differ significantly between groups (P = 0.757). CONCLUSIONS: After long-term follow-up, the hypofractionated radiotherapy regimen of 45 Gy /9 fractions showed encouraging survival outcomes and acceptable toxicity in patients with localized PC. In the propensity score-matched analysis, no statistically significant differences in oncologic outcomes were observed between the 45 Gy/9 fractions regimen and the moderately hypofractionated regimen, while lower gastrointestinal toxicity was observed in the 45 Gy/9 fractions group. however, this finding should be interpreted cautiously in light of the limited sample size, non-randomized design, and technical differences between the cohorts. TRIAL REGISTRATION: ChiCTR-ONC-12001895. Registered retrospectively on 28 January 2012.
引用
- Han Y, Zhong S, Dong X, et al. Effect comparison between a new hypofractionated radiotherapy regimen and conventional moderately hypofractionated regimen for localized prostate cancer. Radiat Oncol. 2026. PMID: 42192417. doi:10.1186/s13014-026-02852-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。